Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Morepen Laboratories' subsidiary Morepen Medipath Limited (MML), which runs the home health business, issued fresh equity shares. The company subscribed to 2,00,000 (Two Lakh) shares under this issue. As a result, Morepen Laboratories' stake in MML fell from 80% to 60%, while the promoter group's stake in MML rose from 20% to 40%. MML's total paid-up share capital increased from 11 lakh shares to 18 lakh shares. Morepen Labs remains the majority shareholder but has given up its earlier controlling 80% position in the new subsidiary.
This is a subsidiary-level restructuring that brings the promoter group in as a more meaningful partner in the home health venture. For shareholders, it signals that the home health business is being separately capitalised, but it also means Morepen Labs is sharing future upside (and decision-making) with the promoter group. Net economic interest remains substantial at 60%, though full control is slightly diluted.